Wong C, Morse M, Nair S K
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
J Immunother. 1998 Jan;21(1):32-40. doi: 10.1097/00002371-199801000-00004.
Using a murine metastasis model, we have previously shown that antigen-presenting cells (APC) loaded with unfractionated peptides derived from poorly immunogenic, highly metastatic tumor cells represent a potent form of tumor vaccine. The antimetastatic effect of peptide pulsed APC could be further enhanced by pretreating the cells with antisense oligonucleotides directed against the TAP-2 gene to increase the density of specific peptide-major histocompatibility complex (MHC) class I complexes and thereby improve the APC function of the treated cells (Nair SK et al., J Immunol 1996;156:1772). In this study, we investigated whether similar strategies can be used to enhance the potency of human dendritic cells (DC) to present antigen. We show that human DC pulsed with peptides encoding known cytotoxic T-lymphocyte (CTL) epitopes stimulate both memory and primary CTL responses in vitro after two cycles of stimulation with the peptide-pulsed DC. Two approaches were used to increase the density of specific peptide-MHC complexes on the surface of DC. One approach was to inhibit transporter associated with antigen presentation (TAP) function using TAP antisense oligonucleotides. The second approach was to inhibit the endogenous generation of the peptide epitopes by pretreating the DC with a proteasome inhibitor. Treatment of DC with either TAP antisense oligonucleotides or with a proteasome inhibitor resulted in a dramatic enhancement of primary CTL induction.
利用小鼠转移模型,我们先前已表明,负载源自低免疫原性、高转移性肿瘤细胞的未分级肽的抗原呈递细胞(APC)代表了一种有效的肿瘤疫苗形式。通过用针对TAP-2基因的反义寡核苷酸预处理细胞,可进一步增强肽脉冲APC的抗转移作用,以增加特异性肽-主要组织相容性复合体(MHC)I类复合体的密度,从而改善处理后细胞的APC功能(Nair SK等人,《免疫学杂志》1996年;156:1772)。在本研究中,我们调查了是否可以使用类似策略来增强人树突状细胞(DC)呈递抗原的能力。我们发现,用编码已知细胞毒性T淋巴细胞(CTL)表位的肽脉冲处理的人DC,在用肽脉冲DC刺激两个周期后,在体外可刺激记忆性和原发性CTL反应。使用了两种方法来增加DC表面特异性肽-MHC复合体的密度。一种方法是使用TAP反义寡核苷酸抑制与抗原呈递相关的转运体(TAP)功能。第二种方法是通过用蛋白酶体抑制剂预处理DC来抑制肽表位的内源性产生。用TAP反义寡核苷酸或蛋白酶体抑制剂处理DC,均可显著增强原发性CTL诱导。